---
document_datetime: 2023-09-21 20:53:14
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/atripla-epar-procedural-steps-taken-authorisation_en.pdf
document_name: atripla-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5224559
conversion_datetime: 2025-12-28 03:25:56.536857
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Bristol-Myers Squibb Gilead Sciences And Merck Sharp &amp; Dohme Limited submitted on  5  October  2006  an  application  for  Marketing  Authorisation  to  the  European  Medicines  Agency (EMEA) for Atripla, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 14 December 2005

•

- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 22 June 2007.

The legal basis for this application refers to: Article 10(b) of Directive 2001/83/EC, as amended - relating to applications for new fixed combination products The  application  submitted  is  a  complete  dossier  composed  of  administrative  information,  complete quality  data,  and  appropriate  non-clinical  and  clinical  data  for  a  new  fixed  combination  medicinal product. The applicant applied for the following indication: 'Atripla is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for use alone as a single tablet regimen or  in  combination  with  other  antiretroviral  agents  for  the  treatment  of  human  immunodeficiency virus-1 (HIV-1) infection in adults.' Scientific Advice: The applicant did not seek scientific advice at the CHMP. Licensing status: Atripla has been given a Marketing Authorisation in the United States of America on 12.07.2006. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: K. Broich Co-Rapporteur: E. Abadie/P. Demolis 2. Steps taken for the assessment of the product · Accelerated Assessment procedure was not accepted by the CHMP on 21 September 2006. · The application was received by the EMEA on 5 October 2006. · The procedure started on 25 October 2006. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 12 January 2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 17 January 2007. · During  the  meeting  on  19-22  February  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 22 February 2007. The applicant submitted the responses to the CHMP consolidated List of Questions on 11 May 2007. Medicinal product no longer authorised

- During the CHMP meeting on 16-19 July 2007, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant  submitted  the  responses  to  the  CHMP  list  of  outstanding  issues  on  10  August 2007.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CHMP members on 3 September 2007.

<div style=\"page-break-after: always\"></div>

- During the CHMP meeting on 17-20 September 2007 it was considered no longer necessary that outstanding issues are addressed by the applicant during an oral explanation before the CHMP.
- During  the  meeting  on  15-18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Atripla on 18 October 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 16 October 2007.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 13 December 2007.

<!-- image -->